Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on July 12th, 2017 by Betsy DavisPharma R&D
In a recent article titled A Spoonful of Kids’ Medicine Makes the Profits Go Up, Kaiser Health News reporter Shefali Luthra wrote about how some pharma industry players may view the need for child-friendly versions of drugs as a “lucrative opportunity”. Luthra specifically cited the opportunities presented by laws like the Best Pharmaceuticals for Children Act Continue reading “Developing Child-Friendly Drugs” »
Posted on July 10th, 2017 by Dr. Makarand Jawadekar, Ph.DPharma R&D
The pharmaceutical industry had really been quite optimistic as of late regarding regulatory overhaul and getting rid of the ever-present ‘red tape’ within the regulatory body in the US, and the FDA had shown a very positive response towards getting biosimilars approved. Continue reading “Biosimilars Development & its Future” »
Posted on July 7th, 2017 by Betsy DavisPharma R&D
Social media is a force to be reckoned with in modern society. Over the last decade, it has changed the way we interact with friends and family, consumes news and entertainment, and do business.
Posted on July 5th, 2017 by Dr. Makarand Jawadekar, Ph.DPharma R&D
These days, there is a lot of focus on nutraceuticals and ‘natural products’, derived from nature or alternately synthesized as ‘nature-identical compounds’ and used in nutraceuticals products. Continue reading “Focus on Nutraceuticals & Natural Products: Medical Use of Cannabis” »
Posted on July 3rd, 2017 by Prima SungChemistry
The rise of in silico approaches has revolutionized early drug discovery, making it possible to model the potential in vivo behaviors of large numbers of compounds, delve deep into their bioactive and chemical properties, Continue reading “The Power of Two in Lead Optimization” »
Posted on June 30th, 2017 by J.-P. Clement MDPharmacovigilance
In a world where many operational and strategic clinical trial activities are outsourced to Contract Research Organizations (CROs), the design and content of the Safety Management Plan (SMP) will greatly influence the execution of clinical trial drug safety activities. Continue reading “The Importance of the Safety Management Plan for Clinical Trials” »
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.